Sexually Transmitted Infections (STIs) Market Expansion Is Opening New Pathways For Strategic Investment

Global Sexually Transmitted Infections (STIs) Market

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Sexually Transmitted Infections (STIs) Market Forecast: What Market Value Is Expected By 2030?

The market for sexually transmitted infections (STIs) has experienced substantial expansion lately. Projections indicate a climb from $71.28 billion in 2025 to $79.48 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.5%. Key factors driving this expansion during the preceding period include an increasing incidence of STIs, restricted availability of prompt diagnostic methods, intensified government-led awareness initiatives, demographic shifts toward urban areas coupled with evolving lifestyles, and a rise in patient consultations at sexual health facilities.

The market for sexually transmitted infections (STIs) is poised for substantial expansion, with projections indicating it will reach $126.99 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.4%. This accelerated growth throughout the projected period is anticipated to be fueled by several key factors: the increasing utilization of sophisticated molecular diagnostic techniques, a surge in the availability and acceptance of at-home STI testing solutions, the growing incorporation of telemedicine services into STI diagnostics and treatment, augmented financial support for initiatives aimed at preventing STIs, and the emergence of artificial intelligence-powered tools for diagnostic support. Key developments anticipated during this forecast period involve the progression of rapid point-of-care STI testing methods, a greater reliance on home-based STI screening kits, advancements in vaccine research and development for STIs, a wider adoption of integrated diagnostic platforms, and amplified public outreach efforts focused on STI prevention.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13047&type=smp

Sexually Transmitted Infections (STIs) Market Demand Drivers: What Is Fueling Industry Growth?

Government efforts to increase public understanding of sexually transmitted infections are poised to stimulate expansion within the STIs market. Such initiatives are designed as specific programs or policies to tackle defined issues and achieve particular objectives. To combat STIs, governments implement a range of measures including allocating funds for awareness campaigns, providing vaccinations for preventable STIs, and offering accessible screening and testing services. For example, a notable initiative launched in April 2023 by Springfield-Greene County Health in the United States, in collaboration with the Missouri Department of Health and Senior Services, introduced the Disease Intervention Specialist (DIS) program. This program aims to address the escalating rates of STIs in Greene County, with specialists focusing on syphilis and HIV. Their role involves reaching out to individuals diagnosed with these infections, connecting them with treatment resources, and notifying their contacts about potential exposure. Consequently, these increasing governmental actions are set to fuel growth in the STIs market.

Sexually Transmitted Infections (STIs) Market Segmentation: How Is The Market Structured Across Key Categories?

The sexually transmitted infections (stis) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), Gonorrhea, Syphilis, Other Types

2) By Treatment: Antibiotics, Antiviral

3) By Location Of Testing: Laboratory Testing, Point-Of-Care (POC) Testing

4) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Human Immunodeficiency Virus (HIV): HIV Type 1, HIV Type 2

2) By Human Papilloma Virus (HPV): Low-Risk HPV, High-Risk HPV

3) By Gonorrhea: Uncomplicated Gonorrhea, Complicated Gonorrhea

4) By Syphilis: Primary Syphilis, Secondary Syphilis, Tertiary Syphilis

5) By Other Types: Chlamydia, Herpes Simplex Virus (HSV), Hepatitis B, Hepatitis C, Trichomoniasis

Sexually Transmitted Infections (STIs) Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading entities within the sexually transmitted infections (STIs) sector are actively pursuing market leadership by creating novel offerings that incorporate fluorescent PCR technology. This advanced molecular biology method, fluorescent PCR, excels at identifying and measuring distinct DNA sequences within biological specimens. To illustrate, in March of 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a Shanghai-headquartered entity specializing in molecular diagnostic systems, unveiled two contemporary PCR kits: the Mycoplasma Hominis Real-Time PCR Kit and the Treponema Pallidum Real-Time PCR Kit. These diagnostic tools present a comprehensive PCR methodology for the timely identification of STIs, conditions affecting a significant number of people. Specifically, the BioPerfectus Mycoplasma Hominis Real-Time PCR Kit operates as a crucial reagent, leveraging fluorescent PCR technology for the detection of Mycoplasma hominis in various human biological samples, including urethral swabs from males, and cervical or vaginal swabs and urine samples from females. Concurrently, the BioPerfectus Treponema Pallidum Real-Time PCR Kit has been engineered to pinpoint treponema pallidum nucleic acid within human serum and plasma samples.

Sexually Transmitted Infections (STIs) Market Competitive Landscape And Leading Companies

Major companies operating in the sexually transmitted infections (stis) market are Pfizer Inc., Johnson & Johnson, Roche Holdings AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Wockhardt Ltd., Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd.

Access The Complete Sexually Transmitted Infections (STIs) Market Report:

https://www.thebusinessresearchcompany.com/report/sexually-transmitted-infections-stis-global-market-report

Sexually Transmitted Infections (STIs) Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the sexually transmitted infection (STIs) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the sexually transmitted infections (stis) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model